tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncowebtumors-549Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISОбзор новых исследований, способных изменить клиническую практику при раке поджелудочной железыПокатаевИ. А.ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Министерства здравоохранения РФ.Russian Federation20181211201883s17681Copyright © Покатаев И.А., 20182018Покатаев И.А.Покатаев И.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/549
.
ReferencesПокатаев И. А., Алиева С. Б, Гладков О. А., Загайнов В. Е., Кудашкин Н. Е., Патютко Ю. И. и соавт. Практические рекомендации по лекарственному лечению рака поджелудочной железы // Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2017 (том 7). С. 367–379.Покатаев И. А., Алиева С. Б, Гладков О. А., Загайнов В. Е., Кудашкин Н. Е., Патютко Ю. И. и соавт. Практические рекомендации по лекарственному лечению рака поджелудочной железы // Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2017 (том 7). С. 367–379.Varadhachary G. R., Tamm E. P., Abbruzzese J. L. et al. Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy // Annals of Surgical Oncology. – 2006. – V 13, N 8. – P. 1035–1046.Varadhachary G. R., Tamm E. P., Abbruzzese J. L. et al. Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy // Annals of Surgical Oncology. – 2006. – V 13, N 8. – P. 1035–1046.Yamada S., Fujii T., Sugimoto H., et al. Aggressive surgery for borderline resectable pancreatic cancer: Evaluation of National Comprehensive Cancer Network guidelines. // Pancreas. – 2013. – V. 42. – P. 1004–1010.Yamada S., Fujii T., Sugimoto H., et al. Aggressive surgery for borderline resectable pancreatic cancer: Evaluation of National Comprehensive Cancer Network guidelines. // Pancreas. – 2013. – V. 42. – P. 1004–1010.Laurence J.M., Tran P.D., Morarji K. al. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. // J Gastrointest Surg. – 2011. – V. 15, N 11. – P. 2059–69.Laurence J.M., Tran P.D., Morarji K. al. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. // J Gastrointest Surg. – 2011. – V. 15, N 11. – P. 2059–69.Van Tienhoven G., Versteijne E., Suker M. et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. // Journal of Clinical Oncology. – 2018. – V. 36, N 18_suppl. – LBA4002.Van Tienhoven G., Versteijne E., Suker M. et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. // Journal of Clinical Oncology. – 2018. – V. 36, N 18_suppl. – LBA4002.Jang J. Y., Han Y., Lee H. et al. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. // Ann Surg. –2018. – V. 268, N 2. – P. 215–222.Jang J. Y., Han Y., Lee H. et al. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. // Ann Surg. –2018. – V. 268, N 2. – P. 215–222.Reni M., Balzano G., Zanon S. et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. // Lancet Gastroenterol Hepatol. – 2018. – Published Online April 3, 2018.Reni M., Balzano G., Zanon S. et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. // Lancet Gastroenterol Hepatol. – 2018. – Published Online April 3, 2018.Hartman D. J., Krasinskas A. M. Assessing treatment effect in pancreatic cancer. // Arch Pathol Lab Med. – 2012. – V. 136. – P. 100–09.Hartman D. J., Krasinskas A. M. Assessing treatment effect in pancreatic cancer. // Arch Pathol Lab Med. – 2012. – V. 136. – P. 100–09.Hammel P., Huguet F., Van Laethem J. et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial // JAMA. – 2016. – V. 315, N 17. – P. 1844–1853.Hammel P., Huguet F., Van Laethem J. et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial // JAMA. – 2016. – V. 315, N 17. – P. 1844–1853.Klaassen D. J., MacIntyre J. M., Catton G. E. et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. // J Clin Oncol. – 1985. – V. 3. – P. 373–378.Klaassen D. J., MacIntyre J. M., Catton G. E. et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. // J Clin Oncol. – 1985. – V. 3. – P. 373–378.Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. // J Natl Cancer Inst. – 1988. – V. 80. – P. 751–755.Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. // J Natl Cancer Inst. – 1988. – V. 80. – P. 751–755.Chauffert B, Mornex F, Bonnetain F, et al.: Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: a FFCDSFRO study. // J Clin Oncol – 2006. – V. 24 (Suppl 18). – A-4008, P. 180s.Chauffert B, Mornex F, Bonnetain F, et al.: Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: a FFCDSFRO study. // J Clin Oncol – 2006. – V. 24 (Suppl 18). – A-4008, P. 180s.Loehrer P. J. Sr, Feng Y., Cardenes H. et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. // J Clin Oncol. – 2011. –V. 29, N 31. – P. 4105–12.Loehrer P. J. Sr, Feng Y., Cardenes H. et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. // J Clin Oncol. – 2011. –V. 29, N 31. – P. 4105–12.Neoptolemos J., Palmer D., Ghaneh P. et al. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. // J Clin Oncol. – 2016. – V. 34 (suppl). – LBA4006.Neoptolemos J., Palmer D., Ghaneh P. et al. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. // J Clin Oncol. – 2016. – V. 34 (suppl). – LBA4006.Neoptolemos J.P., Stocken D.D., Friess H. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. // N Engl J Med – 2004. – V. 350. – P. 1200–10.Neoptolemos J.P., Stocken D.D., Friess H. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. // N Engl J Med – 2004. – V. 350. – P. 1200–10.Neoptolemos J.P., Moore M.J., Cox T.F. et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. // JAMA. – 2012. – V. 308, N 2. – P. 147–56.Neoptolemos J.P., Moore M.J., Cox T.F. et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. // JAMA. – 2012. – V. 308, N 2. – P. 147–56.Oettle H., Neuhaus P., Hochhaus A. et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. // JAMA. – 2013. – V. 310, N 14. – P. 1473–81.Oettle H., Neuhaus P., Hochhaus A. et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. // JAMA. – 2013. – V. 310, N 14. – P. 1473–81.Conroy T., Hammel P., Hebbar M. et al. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. // Journal of Clinical Oncology – 2018. – V. 36, N 18_suppl. – LBA 4001.Conroy T., Hammel P., Hebbar M. et al. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. // Journal of Clinical Oncology – 2018. – V. 36, N 18_suppl. – LBA 4001.Hall B.R., Cannon A., Atri P. et al. Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. // Oncotarget. – 2018. – V. 9, N 27. – P. 19396–19405.Hall B.R., Cannon A., Atri P. et al. Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. // Oncotarget. – 2018. – V. 9, N 27. – P. 19396–19405.Nagriala A.M., China V.T., Sjoquistc K.M. et al. Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials // Critical Reviews in Oncology/Hematology. – 2015. –V. 96. – P. 483–497.Nagriala A.M., China V.T., Sjoquistc K.M. et al. Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials // Critical Reviews in Oncology/Hematology. – 2015. –V. 96. – P. 483–497.Dahan L., Phelip J.M., Le Malicot K. et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX). // Journal of Clinical Oncology. – 2018. –V. 36, N 15_suppl. – P. 4000.Dahan L., Phelip J.M., Le Malicot K. et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX). // Journal of Clinical Oncology. – 2018. –V. 36, N 15_suppl. – P. 4000.NCCN Clinical Practice Guidelines in Oncology, Pancreatic Adenocarcinoma, v 2.2018. Published online 10.07.2018. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf .NCCN Clinical Practice Guidelines in Oncology, Pancreatic Adenocarcinoma, v 2.2018. Published online 10.07.2018. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf .Maitra A., Hruban R.H. Pancreatic cancer. // Annu Rev Pathol. – 2008. – V. 3. – P. 157–188.Maitra A., Hruban R.H. Pancreatic cancer. // Annu Rev Pathol. – 2008. – V. 3. – P. 157–188.Jones S., Zhang X., Parsons D.W. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. // Science. – 2008. – V. 321. – P. 1801–1806.Jones S., Zhang X., Parsons D.W. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. // Science. – 2008. – V. 321. – P. 1801–1806.Hidalgo M. Pancreatic cancer. // N Engl J Med. – 2010. – V. 362. – P. 1605–1617.Hidalgo M. Pancreatic cancer. // N Engl J Med. – 2010. – V. 362. – P. 1605–1617.Pishvaian M.J., Bender R.J., Halverson D. et al. Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor Initiative. //–Clin Cancer Res. – 2018. – In printPishvaian M.J., Bender R.J., Halverson D. et al. Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor Initiative. //–Clin Cancer Res. – 2018. – In printFrogne T., Laenkholm A.V., Lyng M.B. et al. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. // Breast Cancer Res. – 2009. – V. 11. – P. R11.Frogne T., Laenkholm A.V., Lyng M.B. et al. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. // Breast Cancer Res. – 2009. – V. 11. – P. R11.Wulfkuhle J.D., Berg D., Wolff C. et al. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. // Clin Cancer Res. – 2012. – V. 18. – P. 6426–35.Wulfkuhle J.D., Berg D., Wolff C. et al. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. // Clin Cancer Res. – 2012. – V. 18. – P. 6426–35.
The authors declare that there are no conflicts of interest present.